Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March...